Skip to main content
SpringerLink
Log in

Heparin and Streptokinase

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. White HD. Is heparin of value in the management of acute myocardial infarction? Cardiovasc Drugs Ther 1996;11:111–119.

    Google Scholar 

  2. Commerford PJ. Heparin after acute myocardial infarction. Cardiovasc Drugs Ther 1996;11:101–109.

    Google Scholar 

  3. Battle RW, Sobel BE. Coronary thrombolysis for treatment of acute myocardial infarction. In: Brown D, ed. Cardiac Intensive Care. Philadelphia: W.B. Saunders, in press.

  4. Sobel BE, Collen D, ed Coronary Thrombolysis in Perspective. Principles Underlying Conjunctive and Adjunctive Therapy. New York: Marcel Dekker, 1993.

    Google Scholar 

  5. Sobel BE, Nachowiak DA, Fry ETA, Bergmann SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to “plasminogen steal” and its implications for coronary thrombolysis. Coron Artery Dis 1990;1:111–119.

    Google Scholar 

  6. Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255–1262.

    Google Scholar 

  7. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987;10:527–529.

    Google Scholar 

  8. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 1991;83:937–944.

    Google Scholar 

  9. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.

    Google Scholar 

  10. Sobel BE. Conjunctive anticoagulation and coronary thrombolysis. Cor Art Dis. 1996;7:489–490.

    Google Scholar 

  11. Sobel BE. Coronary thrombolysis. Cor Art Dis 1990;1:3–50.

    Google Scholar 

  12. Sobel BE, Hirsh J. Principles and practice of coronary thrombolysis and conjunctive treatment. Am J Cardiol 1991;68:382–388.

    Google Scholar 

  13. Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255–1262.

    Google Scholar 

  14. Rapold HJ, Kuemmerli H, Wiess M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989;79:980–989.

    Google Scholar 

  15. Fitzgerald DJ, Catella F, Roy L, FitzGerald, GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142–150.

    Google Scholar 

  16. ISIS-2 Investigators. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349–360.

    Google Scholar 

  17. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.

    Google Scholar 

  18. The Multicenter Acute Stroke Trial—Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145–150.

    Google Scholar 

  19. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.

    Google Scholar 

  20. Sobel BE, Collen D. Questions unresolved by the Third International Study of Infarct Survival. Am J Cardiol 1992;70:386–389.

    Google Scholar 

  21. Sobel BE, Collen D. Strokes, statistics and sophistry in trials of thrombolysis for acute myocardial infarction. Am J Cardiol 1993;71:424–427.

    Google Scholar 

  22. Shatos MA, Doherty JM, Penar PL, Sobel BE. Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Circulation 1996;94:636–642.

    Google Scholar 

  23. Sobel B. Intracranial bleeding, fibrinolysis, and anticoagulation. Causal connections and clinical implications. Circulation 1994;90:2147–2152.

    Google Scholar 

  24. Tiefenbrunn AJ, Ludbrook PA. Coronary thrombolysis—it's worth the risk. JAMA 1989;261:2107–2108.

    Google Scholar 

  25. Third International Study of Infarct Survival Collaborative Group (ISIS-3). A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.

    Google Scholar 

  26. Moschos CB, Oldewurtel HA, Haider B, Regan TJ. Effect of coronary thrombus age on fibrinogen uptake. Circulation 1976;54:653–656.

    Google Scholar 

  27. Mueller HS, Rao PS, Greenberg MA, et al. Systemic and transcardiac platelet activity in acute myocardial infarction in man. Resistance to prostacyclin. Circulation 1985;72:1336–1345.

    Google Scholar 

  28. Parise P, Hauert J, Iorio A, Callegari P, Agnelli G. Streptokinase and rt-PA activate platelets by a different way: Implications on the rethrombosis rate after their administration in myocardial infarction. J Lab Clin Med 1995;125:212–221.

    Google Scholar 

  29. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 1995;92:3323–3330.

    Google Scholar 

  30. Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993;22:296–301.

    Google Scholar 

  31. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993–1003.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, The University of Vermont, College of Medicine, Burlington, Vermont and Fletcher Allen Health Care, Burlington, Vermont, USA

    Burton E. Sobel

Authors
  1. Burton E. Sobel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sobel, B.E. Heparin and Streptokinase. Cardiovasc Drugs Ther 11, 97–100 (1997). https://doi.org/10.1023/A:1007772412098

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007772412098

Search

Navigation